Related references
Note: Only part of the references are listed.CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma
David J. H. Shih et al.
NATURE GENETICS (2020)
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial
Douglas Adkins et al.
LANCET ONCOLOGY (2019)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Erik S. Knudsen et al.
TRENDS IN CANCER (2017)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M. Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson et al.
JAMA ONCOLOGY (2016)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin et al.
LANCET ONCOLOGY (2015)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos et al.
CANCER DISCOVERY (2015)
Clinical Discussion and Review of the Management of Brain Metastases
Priscilla K. Brastianos et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Cyclin dependent kinases in cancer Potential for therapeutic intervention
Miriam Canavese et al.
CANCER BIOLOGY & THERAPY (2012)
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
A. Kathleen McClendon et al.
CELL CYCLE (2012)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
Karine Michaud et al.
CANCER RESEARCH (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
